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Abstract
Anemia during pregnancy and the postpartum period is com-
monly caused by iron deficiency and is a significant world-
wide issue with severe consequences for both mother and
developing fetus. From a worldwide perspective, iron-defi-
ciency anemia (IDA) during pregnancy is highest in the
Asia-Pacific region; however, there has been little guidance
in this region for safe and effective treatment. An expert
panel was convened to develop a concise and informative
set of recommendations for the treatment of IDA in pregnant
and postpartum women in the Asia-Pacific region. This man-
uscript provides these recommendations and aims to reduce
the morbidity and mortality associated with IDA in pregnant
and postpartum women in the Asia-Pacific region. The con-
sensus recommendations define anemia as a hemoglobin
(Hb) level -10.5 g/dL during pregnancy and -10 g/dL dur-
ing the postpartum period, and provide cut-off Hb levels to
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initiate therapy with oral iron, intravenous iron or red blood
cell transfusion.
Keywords: Anemia; iron deficiency; iron therapy; postpar-
tum; pregnancy.
Introduction
Anemia is one of the most prevalent diseases worldwide,
affecting 24.8% of the human population (1.62 billion peo-
ple) (Table 1), and is a major health concern w3, 29x. Iron
shortage is the single most common nutritional deficit in the
world w3, 8x and is the major cause of anemia, accounting
for approximately 50% of cases w28, 29x. The prevalence of
iron-deficiency anemia (IDA) varies among countries but is
a particular problem in the developing world, reflecting dif-
ferences in race, socio-economic factors, nutritional habits,
medical care and the frequency of parasitic illnesses w8x.
Numerous countries conduct interventions to reduce anemia,
particularly in susceptible groups, such as pregnant women
and young children.
Anemia during pregnancy is a significant concern with the
World Health Organization (WHO) estimating a prevalence
of 41.8% amongst pregnant women (Table 1) w29x. Iron
demand increases rapidly in the second and third trimester
of pregnancy with the needs of the developing fetus, with a
daily requirement of up to 10 mg w21x. Iron absorption from
the diet also increases during pregnancy through upregula-
tion of iron transporters in the gut w19x; however, this
increase in absorption is not sufficient to meet the demand
during the latter stages of pregnancy. Therefore, iron balance
depends largely upon maternal iron stores w8, 9x. A pre-preg-
nancy store of more than 500 mg of iron is required to avoid
iron deficiency during pregnancy, yet such adequate levels
of iron are only present in 20% of menstruating women
before pregnancy ensues w3x. These iron store deficits are
exacerbated by the blood loss experienced during the deliv-
ery process and add to the considerable risk of developing
postpartum anemia w9x.
The consequences of IDA during pregnancy are often seri-
ous and long lasting for both the mother and fetus w8, 22x
(Table 2). Expectant mothers with anemia often experience
increased fatigue levels, reduced exercise performance and
reduced mental performance w8, 22x. Furthermore, severe
anemia whemoglobin (Hb) -9 g/dLx is related to an
increased risk of prematurity, small for gestational-age babies
and spontaneous abortion w8x. Fetal iron metabolism is com-
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Table 1 Worldwide estimated prevalence of anemia w29x.
Population group Prevalence (%)
Pre-school-age children 47.4
School-age children 25.4
Pregnant women 41.8
Non-pregnant women 30.2
Men 12.7
Elderly 23.9
Total population 24.8
Reproduced with permission from the World Health Organization.
Table 2 Consequences of IDA during pregnancy and postpartum
w8, 9, 20, 22x.
Mother Fetus
• Fatigue • Increased mortality
• Increased risk for blood transfusion • Reduced birth weight
• Reduced physical performance • Increased preterm birth
• Reduced mental performance • Growth retardation
• Infection • Neurologic impairment
• Risk of hospitalization • Impaired placental
• Inhibited lactation growth
• Postpartum depression: ‘‘baby
blues’’
IDAsiron-deficiency anemia.
Table 3 European and North American guidelines for the treatment of IDA during pregnancy w5, 11, 20x.
Swiss Society of Obstetrics and Gynaecology The Network for Advancement of Transfusion
Alternatives (NATA)
Pregnancy
• Oral iron in patients with mild-to-moderate IDA • Oral iron in first and second trimester
(Hb 9–10.5 g/dL) • Consider i.v. iron after 14 weeks’ gestation
• I.v. iron in second and third trimester in patients: in patients unresponsive to oral iron
– Unresponsive to oral iron (Hb increase -0.5 g/dL in 2 weeks)
– With severe IDA (Hb -9 g/dL) • I.v. iron in third trimester in case of IDA
– With other factors such as requirement for • If available, test serum ferritin for iron stores
rapid repletion (Jehovah’s Witnesses etc)
Postpartum
• Oral iron in patients with mild anemia • Without ongoing bleeding
(Hb 9.5–12 g/dL) • I.v. iron if Hb 6–9.5 g/dL
• I.v. iron in moderate-to-severe anemia – ESA can be used in non-responders
(Hb 8.5–9.5 g/dL) • Consider transfusion if Hb -6 g/dL
– Consider ESAs if Hb -8 g/dL • Early after delivery, ferritin is false normal
• Consider transfusion if Hb -6 g/dL Do not test before 6–12 weeks after birth
IDAsiron-deficiency anemia; i.v.sintravenous; ESAserythropoiesis-stimulating agent; Hbshemoglobin.
pletely dependent upon maternal iron delivery via the pla-
centa and so the effects of anemia on the fetus are directly
related to the extent of maternal iron deficiency with
increased mortality linked to severe IDA w8x. Considerable
efforts to decrease the prevalence of IDA during pregnancy
through preventative methods have been largely unsuccess-
ful, and access to new therapies, such as intravenous (i.v.)
iron and erythropoiesis-stimulating agents (ESAs), readily
available in the USA or Europe, can be limited in settings
where resources are scarce and guidance is negligible.
Currently, there are three main options for the treatment
of IDA: oral iron, i.v. iron and red blood cell transfusion.
ESAs can also be used to treat anemia in some situations
w7x. Recent recommendations, published in Europe and North
America, include oral iron for the treatment of mild-to-mod-
erate IDA during pregnancy with i.v. iron suggested for those
unresponsive to oral treatment w20x (Table 3). The high costs
associated with therapies, such as ESAs often prevent their
use in some of the world’s developing regions where anemia
is most common.
Treatment of IDA arising during pregnancy
and the postpartum period
Oral iron
Oral iron, administered in the form of ferrous sulphate, fer-
rous fumerate, ferrous gluconate or iron hydroxide polymal-
tose complex, is considered the current standard for the
treatment of IDA and is most commonly prescribed in cases
of mild-to-moderate anemia w8, 9x. The benefits of oral iron
intervention include ease of use since no medical expertise
is required for administration. However, limited efficacy and
low patient compliance are often an issue, particularly due
to gastrointestinal side effects w18, 20x. As such, oral iron
may take a long time to correct IDA. Moreover, among the
different oral iron preparations, ferrous salts, but not a pol-
ysaccharide-ferric iron complex lead to oxidative stress as
evidenced by increased levels of non-transferrin bound iron
(or NTBI) w14x.
I.v. iron
The use of i.v. iron to treat IDA in pregnant women was first
examined almost 60 years ago; enhanced Hb levels following
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Table 4 Estimated prevalence of anemia in pregnant women (1993–2005) w29x.
WHO region Prevalence of anemia in Number of pregnant women
pregnant women affected (millions)
(%) w95% CIx w95% CIx
Africa 57.1 w52.8–61.3x 17.2 w15.9–18.5x
Americas 24.1 w17.3–30.8x 3.9 w2.8–5.0x
Southeast Asia 48.2 w43.9–52.5x 18.1 w16.4–19.7x
Europe 25.1 w18.6–31.6x 2.6 w2.0–3.3x
Eastern Mediterranean 44.2 w38.2–50.3x 7.1 w6.1–8.0x
Western Pacific 30.7 w28.8–32.7x 7.6 w7.1–8.1x
Global 41.8 w39.9–43.8x 56.4 w53.8–59.1x
Reproduced with permission from the World Health Organization, CIsconfidence interval; WHOsWorld Health Organization.
Table 5 Overview of treatment practice according to the panel members.
Country Average Prevalence of IDA Country-specific Hb cut-offs for treatment (based on available
patient guidelines? guidelines or own practice experience)
age (years)
Bangladesh 25 50% pregnancy Institute of Public Health First trimester
50% postpartum and Nutrition (IPHN) 2002 • )10 g/dL (oral iron)
(oral iron and blood • -10 g/dL (i.v. iron)
transfusion) Second and third trimester
• -9 g/dL (i.v. iron)
• -8 g/dL (blood transfusion)
China 28–30 6% pregnancy Yes (oral iron, i.v. iron and First trimester
7% postpartum blood transfusions) • )10 g/dL (oral iron)
Second and third trimester
• -9 g/dL (oral iron)
• -7 g/dL (i.v. iron)
• -8 g/dL before delivery (blood transfusion)
Indonesia 8–48 67% pregnancy Yes (oral iron, i.v. iron) Second and third trimester
72% postpartum • -10 g/dL (i.v. iron)
• -7 g/dL (blood transfusion)
Pakistan 22–34 88% pregnancy None 7–9 g/dL
Postpartum: no data • 14–36 weeks (i.v. iron)
• )36 weeks (blood transfusion)
6–7 g/dL
• Asymptomatic (i.v. iron)
• Symptomatic (blood transfusion)
-6 g/dL
• Blood transfusion
Philippines 35 44% pregnancy None • )8 g/dL oral iron
43% postpartum • -8 g/dL blood transfusion
• Avoid blood transfusion if possible
Singapore 25–30 10–24% pregnancy None First to third trimester
Postpartum: no data • 8–11 g/dL (oral iron/i.v. iron)
• -8 g/dL (blood transfusion)
Thailand 25–30 10–24% pregnancy None First and third trimester
Postpartum: no data • 7–11 g/dL (oral iron)
• -7 g/dL (blood transfusion)
Second trimester
• 7–10.5 g/dL (oral iron)
• -7 g/dL (blood transfusion)
Vietnam 15–50 32% pregnancy None • G8 g/dL oral ironqfolate
Postpartum: no data • -8 g/dL blood transfusionqfolate
IDAsiron-deficiency anemia; Hbshemoglobin; i.v.sintravenous.
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Table 6 Overview of key treatment issues for the Asia-Pacific region.
Education • In some areas, testing for anemia is not seen as a priority since severe anemia is not perceived as a major problem
• Issues surrounding the prescription of oral iron and blood transfusions based on empirical rather than evidence-based
experience
• Patients avoid injections which means that physicians have less experience in giving them
• Fear of iron-dextran anaphylaxis from previous trials
• Physicians are unaware of the difference between i.v. iron dextran and i.v. iron sucrose
• Lack of information on i.v. iron use
• Lack of guidelines for the use of i.v. iron in pregnancy
Cause of anemia • Factors other than iron deficiency can cause anemia
• Thalassemia is prevalent in the Asia-Pacific region
Diet • Low iron diet compared with Europe and North America
• Socio-economic background can result in greater risk of iron deficiency
Transfusions • Infection risk (HIV, hepatitis B and C) w7x w24x
• Shortage of available blood
• Cost
Cost of i.v. iron • Governments may not finance treatment
• Where governments do not fund treatments, patients cannot afford i.v. iron themselves
Accessibility • Many patients do not have easy access to medical care
• Difficult to get patient to travel to see physician or get medication to patient
• Large hospitals have good facilities but many deprived areas have poor facilities
i.v.sintravenous; HIVshuman immunodeficiency virus.
i.v. iron sucrose administration were demonstrated while iron
not utilized by the hematopoietic tissues helped replenish
maternal iron stores w17x. More recent studies have demon-
strated i.v. iron to be more efficient than oral iron at increas-
ing Hb levels and replenishing iron stores w1, 4, 6x. The
recently published recommendations for the treatment of
IDA in pregnancy include i.v. iron as an effective alternative
to oral iron during the second and third trimester for pregnant
women who fail to respond to oral iron therapy w10x (Table 3).
I.v. iron preparations include iron sucrose, sodium ferric
gluconate, low molecular weight iron dextran and newer
‘‘next generation’’ preparations, such as ferric carboxymal-
tose w10x; however, these preparations have substantially dif-
ferent safety profiles w2x. For example, dextran-containing
i.v. iron preparations have been shown to be associated with
an increased risk of anaphylactic reactions w2x, whilst iron
sucrose and sodium ferric gluconate are associated with few-
er side effects w2x. Furthermore, subtle structural variations
between the iron sucrose formulations produced by different
manufacturers may affect the stability of the iron complex
and, in turn, the safety and efficacy profile w26x.
Additionally, numerous studies have demonstrated the effi-
cacy and safety of i.v. iron sucrose in pregnant (second and
third trimester) w1, 12x and postpartum women w6, 10x. Expe-
rience with i.v. iron sucrose in the Asia-Pacific region is
growing w16, 24, 27x and data are comparable to results from
European studies w6, 12x, demonstrating that i.v. iron sucrose
is effective, provides rapid correction of anemia and is well
tolerated in treating IDA during pregnancy w16, 24, 27x.
Packed cells or red blood cell transfusion
Although blood transfusions are an effective treatment for
IDA, since they deliver exactly what the body needs (red
blood cells) without any further physiological effort, they do
not correct the underlying cause of anemia. Furthermore,
there are many inherent risks involved with this treatment,
including serious infection, incorrect transfusion, negative
impact on the immune system and transfusion reactions w7,
13x. Additionally, certain groups of the population may
refuse blood transfusions due to religious beliefs, and limited
blood supply often means that stock is reserved for emer-
gencies. Therefore, the administration of a blood transfusion
should be considered as a last resort when a patient is unre-
sponsive to i.v. iron supplementation or is in a critical
condition.
Managing IDA in pregnant and postpartum
women in the Asia-Pacific region – present
situation
The prevalence of anemia during pregnancy and the post-
partum period is a particular problem in the Asia-Pacific
region where it is the highest worldwide. In Southeast Asia
and the Western Pacific, 48.2% and 30.7% of pregnant wom-
en have anemia, but some data indicate that prevalence could
be as high as 85.6% and 90.2%, respectively w29x (Table 4).
In this region, oral iron and blood transfusions are currently
the most common therapies for the treatment of IDA (Table
5). However, these strategies are suboptimal since oral iron
is slow to increase Hb to desired levels in moderate-to-severe
anemia. Moreover, a limited availability of blood donors,
high costs and risk of infection means that blood transfusions
should only be used sparingly in very serious cases w7, 13x.
It is, therefore, vital that effective guidelines for the treatment
of IDA in pregnancy are developed for the Asia-Pacific
Breymann et al., Intravenous iron for the treatment of anemia in obstetrics 117
Article in press - uncorrected proof
Figure 1 Consensus recommendations for the treatment of IDA during pregnancy in the Asia-Pacific region. IDAsiron-deficiency anemia.
region to ensure prompt intervention and optimal care of the
mother and developing fetus.
Physicians throughout the Asia-Pacific region face a range
of unique challenges when managing IDA in pregnant and
postpartum women (Table 6). In some areas, testing for and
treatment of anemia during pregnancy are not a priority since
there is an acceptance that anemia is commonplace in the
general population accompanied by a lack of perception of
the consequences of maternal IDA. Also, the high prevalence
of thalassemia and malaria in some regions complicates diag-
nosis and treatment; therefore, identifying the cause of ane-
mia is essential before intervention is initiated. Access to the
appropriate therapy is often an issue with geographic and
economic barriers, preventing optimal care of patients in
greatest need.
Evidence of the efficacy and safety of i.v. iron as a treat-
ment for IDA is growing through a number of international
trials w1, 4, 6, 10, 12, 15, 16x. These studies have shown a
rapid correction of anemia and a reduced risk of blood trans-
fusions in the peripartum and postpartum period. As a result,
the use of i.v. iron as a treatment for IDA has increased in
Europe in the obstetric/gynecologic setting. Similar studies
at the local level in the Asia-Pacific region have been lacking
and consequently the use of i.v. iron in this region has been
limited. Other issues including fear of adverse events, avail-
ability of resources and economic viability (Table 6) also
restrict the use of i.v. iron in these communities. However,
intervention with i.v. iron is expected to grow in the Asia-
Pacific region in parallel with evidence from recent trials
conducted in this section of the population w16, 24, 27x.
Recommendations for diagnosis and treatment
of IDA in pregnancy in the Asia-Pacific region
Accepted guidelines to assist physicians treating pregnant
women with IDA are lacking in the Asia-Pacific region. An
expert panel (Appendix), of physicians involved in the treat-
ment of anemia in the obstetrics/gynecology setting and with
long-term experience of iron therapy, was convened to devel-
op a concise and informative set of recommendations for the
treatment of IDA in pregnant and postpartum women in the
Asia-Pacific region. This manuscript provides these recom-
mendations and aims to raise awareness of the safety and
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Figure 2 Consensus recommendations for the treatment of IDA during the postpartum period in the Asia-Pacific region. IDAsiron-
deficiency anemia.
efficacy of treatments available for IDA to meet the requi-
rements of pregnant and postpartum women in the Asia-
Pacific region.
Diagnosis of IDA during pregnancy in the Asia-Pacific
region
Anemia in pregnancy is defined by the Center for Disease
Control and Prevention as an Hb level of below 11 g/dL in
the first and third trimester and an Hb below 10.5 g/dL in
the second trimester w23x; likewise, the WHO define anemia
in pregnancy as an Hb level below or equal to 11 g/dL w29x.
The Hb cut-off levels currently used in practice are often
lower than these levels (Table 5); hence, it is important to
raise awareness of the criteria used for the diagnosis of ane-
mia in pregnant women. A hematologic profile, including Hb
levels and hematocrit, enables the diagnosis of anemia w8x
and biochemical markers of iron levels are important for
determining the cause of anemia before treatment is initiated.
To identify IDA, both Hb (an indicator of anemia) and serum
ferritin (an indicator of iron storage) should be assessed: low
ferritin levels indicate iron deficiency, while normal-to-high
ferritin levels can indicate thalassemia, lead poisoning and
inflammation w25x. Therefore, the appropriate use of markers
for iron levels should be established to aid the diagnosis of
IDA during pregnancy and the postpartum period.
Consensus recommendations for diagnosis of IDA
during pregnancy in the Asia-Pacific region
• Hb -10.5 g/dL
• Ferritin -20 mg/L
• If ferritin )20 mg/L, other causes of anemia such as thalassemia
and vitamin B12 deficiency should be excluded
– Consider C-reactive protein assessment to rule out underlying
infection (causes elevated ferritin levels)
Consensus recommendations for diagnosis of IDA
during the postpartum period in the Asia-Pacific region
• Hb -10 g/dL
• Ferritin measurement is not recommended in the early postpartum
period since it can be normal or elevated due to inflammation
• Treatment can commence once:
– The cardiovascular system is stable
– There is no ongoing bleeding
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Treatment of IDA in pregnancy and the postpartum
period in the Asia-Pacific region
Due to the serious consequences of IDA in pregnancy,
prompt and effective intervention is required (Tables 2 and
3). It is important to note that i.v. iron and oral iron are only
licensed for the treatment of iron deficiency. Furthermore,
the use of i.v. iron is contraindicated during the first trimester
of pregnancy. However, the use of i.v. iron is considered safe
in the second and third trimester w20x. It is, therefore, advis-
able to check the labels for both oral and i.v. iron compounds
prior to their administration. The consensus recommenda-
tions (Figures 1 and 2) target the application of oral iron, i.v.
iron and blood transfusion to specific severities of IDA
(stratified by Hb level) to ensure the safest and most efficient
treatment possible. The Hb cut-off values were agreed by the
expert panel to indicate the need for treatment of IDA during
pregnancy (Figure 1) and the postpartum period (Figure 2).
Areas requiring further consideration
Recent studies have demonstrated the efficacy and safety of
i.v. iron in pregnant (second and third trimester) w1, 4, 12x
and postpartum women w6, 12x. Experience with i.v. iron in
the Asia-Pacific region is growing w16, 24, 27x. However,
further studies in this region are warranted to enhance con-
fidence in the use of i.v. iron among prescribing physicians.
Measures to raise awareness of the consequences of IDA are
also required to ensure the appropriate testing and prompt
treatment of anemia during pregnancy and the postpartum
period.
Conclusions
IDA is the most frequent form of anemia during pregnancy
and can have serious consequences for both the mother and
fetus. The majority of women do not have adequate iron
stores to meet the dramatic increase in requirements during
the second and third trimester of pregnancy. From a world-
wide perspective, IDA in pregnancy is highest in the Asia-
Pacific region; however, there has been little guidance in this
region for the safe and effective treatment of IDA during
pregnancy and the postpartum period. Currently, the main
interventions in this region are oral iron and blood transfu-
sions. However, i.v. iron is more effective, provides more
rapid Hb correction, corrects iron stores and is better toler-
ated than oral iron in treating IDA during pregnancy w1, 4,
10x. Furthermore, recent studies have demonstrated the effi-
cacy and safety of i.v. iron in the second and third trimester
of pregnancy w1, 4, 10x and in postpartum women w6, 10x.
The goal of the recommendations presented here is to reduce
the morbidity and mortality associated with IDA in pregnant
and postpartum women in the Asia-Pacific region. Consen-
sus recommendations include a definition of anemia as an
Hb level below 10.5 g/dL in pregnancy and below 10 g/dL
in the postpartum period. The panel also advocates the use
of i.v. iron in the second and third trimester of pregnancy to
correct anemia and reduce the risk of transfusion in the post-
partum period. Further randomized phase III trials with i.v.
iron in the Asia-Pacific region are warranted to optimize
clinical outcomes for the mother and developing fetus.
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